OC
Oculis Holding AG
OCS · NASDAQ
$9.06 -1.52% (-$0.14)
1M -26.04%
Market Cap CHF 430.9M
P/E Ratio -
Div. Yield -
ROE 42.92%
Bulios Fair Price
$7.13
21.3% downside
Current Price
$9.06
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OCS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
44 /100
Fair P/B 1.96x
P/S 1,773.09x
PEG N/A
Growth
-
N/A Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
14 /100
Weak FCF margin 27,181.90%
Op. margin 35,874.20%
Gross margin 35.21%
Quality
0 /100
Poor Asset turnover 0.00x
ROA 31.82%
ROIC 38.94%
Debt
69 /100
Low Current ratio 8.35x
Int. coverage -85.17x
Debt/Equity 0.01x
Stability
4 /100
Unstable EPS volatility 100.31%
Profitable years 0
Beta 0.23x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OCS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Riad Sherif
Employees
60
Headquarters
Zug
Upcoming events
05 NOV
Earnings
Upcoming earnings report